| Lung Cancer Treatments and Mutations | Lifetime | 3 | US 3 | 99.97 |
| Lung Cancer Research Studies | Lifetime | 4 | US 3 | 99.95 |
| Colorectal Cancer Treatments and Studies | Lifetime | 7 | US 4 | 99.92 |
| Cancer therapeutics and mechanisms | Lifetime | 14 | US 9 | 99.77 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 20 | US 9 | 99.85 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 37 | US 22 | 99.89 |
| Gastric Cancer Management and Outcomes | Lifetime | 241 | US 85 | 99.37 |
| Immunotherapy and Immune Responses | Lifetime | 322 | US 172 | 99.44 |
| CAR-T cell therapy research | Lifetime | 204 | US 129 | 99.29 |
| Cancer Genomics and Diagnostics | Lifetime | 380 | US 225 | 99.29 |
| HER2/EGFR in Cancer Research | Lifetime | 155 | US 78 | 99.25 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 201 | US 74 | 98.98 |
| Brain Metastases and Treatment | Lifetime | 311 | US 183 | 97.83 |
| Renal cell carcinoma treatment | Lifetime | 521 | US 283 | 97.83 |
| Peptidase Inhibition and Analysis | Lifetime | 952 | US 420 | 97.11 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 478 | US 268 | 96.47 |
| vaccines and immunoinformatics approaches | Lifetime | 610 | US 279 | 93.99 |
| Advanced Breast Cancer Therapies | Lifetime | 796 | US 333 | 93.90 |
| Quinazolinone synthesis and applications | Lifetime | 747 | US 126 | 90.36 |
| Chemotherapy-related skin toxicity | Lifetime | 872 | US 383 | 80.52 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 15 | US 5 | 99.90 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 26 | US 5 | 99.56 |
| Lung Cancer Research Studies | 2021-2025 | 17 | US 5 | 99.74 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 18 | US 6 | 99.75 |
| Cancer Genomics and Diagnostics | 2021-2025 | 98 | US 55 | 99.18 |
| Cancer therapeutics and mechanisms | 2021-2025 | 19 | US 7 | 98.26 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 153 | US 34 | 98.38 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 361 | US 140 | 98.62 |
| HER2/EGFR in Cancer Research | 2021-2025 | 117 | US 42 | 98.22 |
| Advanced Breast Cancer Therapies | 2021-2025 | 318 | US 114 | 94.27 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 321 | US 119 | 76.61 |
